 The Covid-19 pandemic has had a significant impact on research in clinical and translational science award, CTSA, hubs. In response, many CTSA members have made adjustments to their workflows and priorities to ensure continued progress in medical research. These changes include the establishment of dedicated diagnostic laboratories, the use of internal funding sources, and the formation of centralized feasibility committees to prioritize and review clinical trials. Additionally, CTSA leaders have been able to quickly adapt to changing circumstances and make decisions regarding research priorities. This article was authored by Dushantha Jayawira, Patrick A. Flume, Nora G. Singer, and others.